Summary Background Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis
(TEN) are severe cutaneous adverse reactions with high morbidity and mortality. Some …

The incidence of malignant melanoma has shown a dramatic increase over the past three
decades. Patient outcome and curability depend on early diagnosis. In vivo multiphoton …

Abstract The 2005 National Institute of Health (NIH) Consensus Conference outlined
histopathological diagnostic criteria for the major organ systems affected by both acute and …

Background Uveal melanoma (UM) is an ocular malignancy with high potential for
metastatic spread. In contrast to cutaneous melanoma, immunotherapy has not yet shown …

Atypical fibroxanthoma (AFX) is a rare neoplastic disease of the skin. Since the term was
coined in the early 1960s, the disease has been viewed in many ways. For a long time AFX …

Background The IMMUNED trial previously showed significant improvements in recurrence-
free survival for adjuvant nivolumab plus ipilimumab as well as for adjuvant nivolumab alone …

To date, there have been only few studies investigating rechallenge with checkpoint
inhibitors in melanoma patients. Herein, we present the first review of all internationally …

Background Ipilimumab and programmed death (PD) 1-antibodies are effective treatment
options in metastatic melanoma. The safety and efficacy of ipilimumab in patients with pre …

Recent studies revealed trajectories of mutational events in early melanomagenesis, but the
accompanying changes in gene expression are far less understood. Therefore, we …

Immuno-oncology therapies are being increasingly used as a principle pharmacological
cancer treatment. The CTLA4-antibody ipilimumab, and PD-1-antibodies pembrolizumab …